Liraglutide Year-1 Outcomes: What Real Users Actually Experience

What the Clinical Trials Say About Year-1 Results

The most reliable starting point for year-1 expectations is the SCALE Obesity and Prediabetes trial, a 56-week randomized controlled study in 3,731 adults without diabetes. Participants on liraglutide 3.0 mg lost a mean of 8.0% of body weight versus 2.6% on placebo, a difference of 5.4 percentage points [1]. About 63.2% of liraglutide-treated participants lost at least 5% of body weight, compared with 27.1% on placebo.

What "Mean" Weight Loss Actually Hides

Averages obscure the full picture. In SCALE, the distribution of responses was wide. Roughly one-third of participants lost more than 10% of body weight, while approximately 20% lost less than 5% despite completing the trial. That spread is important for setting realistic expectations before month 1.

The SCALE Diabetes trial, which enrolled 846 adults with type 2 diabetes, showed a more modest mean weight loss of 6.0% at 56 weeks on liraglutide 3.0 mg versus 2.0% on placebo [2]. Lower baseline insulin sensitivity and competing medications partially explain the attenuated response in this population.

Cardiovascular Signal at One Year

The LEADER trial (N=9,340 adults with type 2 diabetes and high cardiovascular risk) ran for a median of 3.8 years on liraglutide 1.8 mg, but the 12-month data showed a 3.4 kg mean weight reduction alongside a 1.1 mmHg reduction in systolic blood pressure and a 0.4% reduction in HbA1c [3]. The FDA approved liraglutide 1.8 mg (Victoza) specifically for cardiovascular risk reduction in this population based on LEADER outcomes.

HbA1c at 12 Months in Diabetes Patients

For patients with type 2 diabetes, liraglutide 1.8 mg produced a mean HbA1c reduction of approximately 1.1 to 1.6% from baseline across the LEAD trial program (LEAD-1 through LEAD-6, collectively enrolling over 4,400 participants) [4]. That magnitude of glycemic reduction is clinically meaningful and exceeds most oral agents tested in head-to-head studies within the same program.

What Real Users Report After 12 Months

Patient review platforms and Reddit communities provide a different lens than controlled trials. They capture experiences with dose escalation struggles, insurance battles, injection site fatigue, and the emotional arc of a year-long therapy. These accounts are not randomized, but patterns emerge at scale.

Reddit: The Dominant Themes at the 12-Month Mark

The r/liraglutide and r/Saxenda communities (combined membership exceeding 40,000 as of early 2025) show recurring patterns in posts tagged "12 months" or "1 year update."

The most consistent theme is variance. Users reporting 10 to 18 kg of weight loss at month 12 and users reporting 2 to 4 kg sit in the same threads, often with similar starting weights. Responders frequently credit slow, deliberate dose titration and high protein intake. Non-responders more often describe rushing the titration to 3.0 mg, developing persistent nausea, and reducing their dose or stopping.

A second theme is nausea management. Eating smaller meals, stopping at early satiety cues, and avoiding high-fat foods are mentioned more reliably than any pharmaceutical intervention. Several users note that nausea largely resolved by week 8 to 10 once they stabilized at their maintenance dose.

A third theme is plateau. Many 12-month posters describe losing 7 to 10% in the first 6 months, then seeing weight loss slow significantly. This matches the pharmacological reality: liraglutide's weight-lowering effect plateaus as the body adapts, and the plateau tends to appear around month 6 to 9 in clinical data as well [1].

Drugs.com and Trustpilot Ratings

On Drugs.com, Saxenda carries a mean rating of approximately 6.8 out of 10 from over 900 reviews. The most common positive themes are reduced hunger and gradual, sustainable weight loss. The most common negative themes are nausea, cost, and inconsistent insurance coverage.

Trustpilot reviews for telehealth providers prescribing liraglutide show similar distributions, with users who reached 3.0 mg without GI problems rating the drug markedly higher than those who could not tolerate full escalation.

Dose Escalation and Why It Predicts Your Year-1 Outcome

Dose escalation is probably the strongest modifiable predictor of year-1 success. The FDA-approved titration schedule for Saxenda starts at 0.6 mg subcutaneous daily for week 1, increases to 1.2 mg for week 2, then 1.8 mg for week 3, 2.4 mg for week 4, and reaches the 3.0 mg maintenance dose at week 5 [5].

The "Slow Titration" Case

A notable portion of real-world users titrate more slowly than the approved schedule, holding each dose for 2 to 4 weeks instead of 1. Many report fewer GI side effects and better long-term adherence using this approach. No published RCT has directly compared 5-week versus 10-week titration schedules for Saxenda specifically, though slower titration is a common clinical practice for GLP-1 receptor agonists broadly [6].

What Happens If You Stop at 1.8 mg

Some users plateau at 1.8 mg due to nausea at 2.4 mg or 3.0 mg. SCALE trial data does not report a separate efficacy arm for 1.8 mg in non-diabetic patients, but the dose-response relationship observed across the LEAD program suggests that 3.0 mg produces meaningfully greater weight loss than 1.8 mg. Stopping short of the target dose likely means a smaller year-1 result.

Injection Site Rotation

Injection site reactions occur in roughly 13 to 14% of Saxenda users in clinical trials [5]. Reddit users frequently cite lipohypertrophy (fat accumulation at repeated injection sites) as a cause of variable absorption and inconsistent effect after month 6. Rotating between the abdomen, thigh, and upper arm on a weekly basis reduces this risk.

Side Effects at the 12-Month Mark: What Persists and What Fades

Most liraglutide side effects are front-loaded. Nausea, vomiting, diarrhea, and constipation are most intense during the first 8 to 12 weeks of dose escalation and generally diminish once a stable dose is reached.

GI Side Effects Over Time

In SCALE, nausea was reported by 39.3% of liraglutide participants versus 13.8% on placebo at some point during the 56-week trial. At week 56, the incidence of active nausea had dropped substantially from its peak during weeks 1 to 8 [1]. Users who tolerate the full titration typically report GI symptoms as a minor or absent issue by month 4 to 5.

Gallbladder Events

Liraglutide carries an FDA-mandated warning for gallbladder disease. In SCALE, cholelithiasis occurred in 2.2% of liraglutide participants versus 0.8% on placebo [1]. Rapid weight loss itself, regardless of method, increases bile saturation and gallstone formation risk. At 12 months, any new right-upper-quadrant pain should prompt hepatobiliary workup.

Thyroid C-Cell Concerns

The Saxenda label carries a black-box warning for thyroid C-cell tumors based on rodent carcinogenicity studies [5]. The FDA notes this has not been confirmed in humans, and the LEADER trial (3.8-year median follow-up) did not detect a statistically significant increase in medullary thyroid carcinoma. Liraglutide remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Psychiatric and Mood Signals

Post-market reports and some user reviews describe mood changes and increased anxiety on liraglutide, particularly during the dose-escalation phase. The FDA added a requirement for pharmacovigilance data on neuropsychiatric events to the GLP-1 class label. No definitive causal signal has been established, but patients with a history of depression or anxiety should be monitored at the 3-month and 6-month marks.

Liraglutide vs. Semaglutide at One Year: How the Real-World Results Compare

Semaglutide 2.4 mg (Wegovy) has largely displaced liraglutide 3.0 mg in the weight-management market since its 2021 approval. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% on placebo [7]. That is roughly double the magnitude seen with liraglutide in SCALE.

Why Some Patients Still Choose Liraglutide

Cost is the primary reason. Compounded liraglutide from 503B outsourcing facilities costs $150, $350 per month through many telehealth platforms, compared with $1,000+ per month list price for brand semaglutide without insurance. Patients who cannot access semaglutide through insurance or cannot afford it often choose liraglutide.

Tolerability is the secondary reason. A subset of patients find daily liraglutide injections easier to titrate than weekly semaglutide. The shorter half-life of liraglutide (13 hours vs. Approximately 7 days for semaglutide) means that side effects from a given dose resolve faster, giving patients more control over their experience during titration [6].

Head-to-Head Data

The SUSTAIN 7 trial compared semaglutide 0.5 mg and 1.0 mg versus liraglutide 0.9 mg and 1.8 mg (at diabetes doses) over 40 weeks. Semaglutide 1.0 mg reduced HbA1c by 1.5% versus 1.0% for liraglutide 1.8 mg, and body weight by 6.5 kg versus 2.0 kg [8]. No head-to-head trial at obesity doses (semaglutide 2.4 mg vs. Liraglutide 3.0 mg) has been published.

Who Responds Best to Liraglutide at 12 Months

Based on published SCALE subgroup analyses and aggregated clinical patterns, the following patient profile is associated with above-average year-1 response:

Higher-response profile:

• Baseline BMI 30 to 40 kg/m2 without type 2 diabetes
• No prior bariatric surgery (GLP-1 receptor density may differ post-surgery)
• Slow, deliberate dose titration over 8 to 12 weeks rather than 5 weeks
• Consistent dietary modification (high protein, low ultra-processed food)
• No concomitant medications that promote weight gain (antipsychotics, corticosteroids, certain antidepressants)

Lower-response profile:

• Type 2 diabetes with long disease duration and high baseline insulin dose
• Prior failure on another GLP-1 receptor agonist at full dose
• Inability to reach 3.0 mg due to persistent GI intolerance
• BMI above 45 kg/m2 (trial data shows proportionally lower percent weight loss at very high baseline weights, though absolute kg loss may be similar)

The American Association of Clinical Endocrinology 2023 obesity guidelines state: "Response should be assessed at 16 weeks; patients who have not lost at least 4% of body weight are unlikely to achieve meaningful long-term benefit and should be considered for dose optimization or alternative therapy" [9].

The Weight Regain Problem After Year 1

Stopping liraglutide after a successful year produces rapid weight regain in most patients. The SCALE Maintenance extension showed that 1 year after discontinuation, participants who stopped liraglutide regained a mean of 50% of their lost weight [10]. One year back on placebo returned most participants close to their original weight.

What This Means for Real Users

Reddit posts from users who stopped Saxenda after reaching a goal weight consistently describe regaining 5 to 15 lbs within 3 to 6 months. Some describe returning to their original weight within 12 to 18 months. This is not a personal failure: liraglutide works by suppressing appetite while the drug is present, and appetite physiology reverts when the drug is withdrawn.

Maintenance Strategies

Clinicians prescribing liraglutide for weight management increasingly treat it as a chronic medication rather than a time-limited course. The Endocrine Society 2023 clinical practice guideline on obesity pharmacotherapy recommends: "Anti-obesity medications should be continued long term if effective and tolerated, similar to treatment of other chronic conditions such as hypertension" [11].

Patients who do transition off liraglutide may reduce regain by maintaining high protein intake (at least 1.2 g/kg/day), resistance training at least 3 days per week, and structured follow-up with a clinician at 3-month intervals.

Compounded Liraglutide: What to Know Before Month 1

Compounded liraglutide is available through many telehealth platforms at lower cost than brand Saxenda. The FDA has not approved any compounded version, and the agency's guidance on compounded GLP-1 products emphasizes that compounded drugs lack the same manufacturing oversight, potency verification, and safety data as FDA-approved products [12].

The FDA removed semaglutide from the drug shortage list in early 2025, which triggered enforcement action against compounded semaglutide. As of mid-2025, liraglutide remains on the FDA shortage list, making compounded liraglutide legally available from 503A pharmacies and 503B outsourcing facilities.

Patients choosing compounded liraglutide should confirm that their pharmacy holds 503B outsourcing facility status, request a certificate of analysis for each lot, and use the same titration schedule as the approved product.